Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04466150 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04466150 · ClinicalTrials.gov record · last posted 2026-01-26

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Study acronym: IMPACT MS
StatusActive, Not Recruiting
PhasePhase 4
Started2020-08-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2020-07-07; most recent amendment 2026-01-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-09-19
Status change Recruiting→Active, Not Recruitingv5
2020-11-16
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT04466150
Lead Sponsor University of California, San Francisco
Collaborators: Genentech, Inc., Valhalla Foundation
Conditions Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Enrollment 30 participants
Start Date 2020-08-30
Primary Completion 2026-12 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-26